Clinical PET Studies in Neuro-Oncology (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 1 December 2024 | Viewed by 1152
Special Issue Editor
2. IADI UMR 1254, INSERM, Université de Lorraine, F-54000 Nancy, France
Interests: PET imaging; amino-acid radiotracers; neuro-oncology; glioma
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
PET imaging is currently recommended as an adjunct to MRI for the assessment of brain tumors. The present Special Issue will focus on PET brain tumor assessment at different stages of the disease, including initial diagnosis, treatment planification, and follow-up studies in clinical practice. All types of brain tumors will be covered, including glioma, brain metastases, meningioma, and primary cerebral lymphoma. Specific attention will be paid to clinical studies with translational research to monitor peptide receptor radionuclide therapy. All of the available PET radiotracers that are useful in neuro-oncology clinical practice will be welcome, including FDG, amino acid radiotracers, DOTATOC PET imaging, and TSPO imaging. The objective of this Special Issue is to provide a complete and comprehensive overview of the potential of PET imaging in neuro-oncology to neuro-oncologists, neurosurgeons, radiologists, and nuclear physicians.
Prof. Dr. Antoine Verger
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PET
- neuro-oncology
- glioma
- meningioma
- lymphoma
- brain metastasis
- amino acid radiotracer
- peptide receptor radionuclide therapy
- DOTATOC
- FDG
- TSPO
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
